Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)

Journal of Diabetes and its Complications

Volumn 28, Issue 3, 2014, Pages 386-392

  Rosenstock, Julio ^a   Hanefeld, Markolf ^b   Shamanna, Paramesh ^c   Min, Kyung Wan ^d   Boka, Gabor ^e   Miossec, Patrick ^e   Zhou, Tianyue ^e   Muehlen Bartmer, Isabel ^f   Ratner, Robert E ^g  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Bangalore Baptist Hospital   (India)

^d Eulji General Hospital   (South Korea)

^e SANOFI   (France)

^f Sanofi R and D   (Germany)

^g MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

GLP 1 receptor agonists; Lixisenatide; Sulfonylurea; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIXISENATIDE; METFORMIN; PLACEBO; PROINSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; SULFONYLUREA DERIVATIVE; ZP10A PEPTIDE;

ADD ON THERAPY; ADULT; AGED; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; TEST MEAL; TREATMENT OUTCOME; URTICARIA; VOMITING; WEIGHT REDUCTION; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG COMBINATION; INTERNATIONAL COOPERATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTERNATIONALITY; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84899545131     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.01.012     Document Type: Article

References (24)

1. B. Ahrén et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) Diabetes Care 36 9 2013 2543 2550
2. V. Aroda, and R. Ratner The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review Diabetes/Metabolism Research and Reviews 27 2011 528 542
3. G. Bolli et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1) Diabetic Medicine 31 2 2013 176 184
4. J. Buse, R. Henry, and J. Han Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
5. D. Drucker The biology of incretin hormones Cell Metabolism 3 2006 153 165
6. V. Fonseca et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Diabetes Care 35 2012 1225 1231
7. IDF Clinical Guidelines Task Force: Global guidelines for Type 2 Diabetes 2005 International Diabetes Federation Brussels
8. S. Inzucchi, R. Bergenstal, and J. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach Diabetes Care 35 16 2012 1364 1379
9. C. Kapitza, T. Forst, and H. Coester Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin Diabetes, Obesity & Metabolism 15 7 2013 642 649
10. D. Kendall, M. Riddle, and J. Rosenstock Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 2005 1083 1091
11. M. Lorenz et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia Regulatory Peptides 158C 2013 1 8
12. M. Marre, J. Shaw, and M. Brandle Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabetic Medicine 26 2009 268 278
13. J. Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nature Reviews Endocrinology 8 12 2012 728 742
14. E. Montanya, and G. Sesti A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus Clinical Therapeutics 31 2009 2472 2488
15. D. Nathan et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
16. M. Nauck, M. Heimesaat, and K. Behle Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers Journal of Clinical Endocrinology and Metabolism 87 2002 1239 1246
17. M. Pinget et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P) Diabetes, Obesity & Metabolism 2013 10.1111/dom.12121
18. R. Ratner et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial Diabetic Medicine 27 2010 1024 1032
19. M. Riddle et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care 36 9 2013 2489 2496
20. M. Riddle et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 36 9 2013 2497 2503
21. H. Rodbard, P. Jellinger, and J. Davidson Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocrine Practice 15 2009 540 559
22. J. Rosenstock et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 2013 10.2337/dc12-2709
23. Y. Seino et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes, Obesity & Metabolism 14 10 2012 910 917
24. U. Werner, G. Haschke, and A. Herling Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes Regulatory Peptides 164 2010 58 64